Ramos-Zavala et al. [9] evaluated the efficacy of diacerein in 40 drug-naïve patients with newly diagnosed T2DM and HbA1c levels between 7% (53 mmol/mol) and 9% (75 mmol/mol) and found a significant absolute reduction of 1.3% (14.2 mmol/mol) in HbA1c as well as in TNF-α and IL-1β levels. This evidence concerns the gene IL1B and type 2 diabetes mellitus.